Biotech | April 29, 2022
Camzyos is the first and only USFDA-approved cardiac myosin inhibitor
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
The round also saw participation from US-based fund 57 Stars, a few prominent angel investors, existing investors Stellaris Venture Partners, Vertex Ventures, and Alteria Capital
These bulk orders will contribute to the topline of the company as well as help in improving EBITDA of the company
Beyond the technical leadership from F1, the collaboration will bring a specific focus on the people dimension of high performance
Results support the development of tislelizumab in potentially synergistic combinations across Novartis advanced therapeutic platforms for the treatment of an array of solid tumours
Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics
The respective expertise of Lonza and Integral Molecular will benefit drug developers in the assessment of the risk for off-target binding and activation
Secretary, Department of Pharmaceuticals and Union Health Secretary Chair a Panel Discussion on the theme 'Indian Pharma Vision 2047'
The approval comes soon after Corbevax was given the nod for 12-15-year group
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
Subscribe To Our Newsletter & Stay Updated
